Olanzapine in the treatment of depression with psychotic features: A prospective open-label study

Adli, Mazda; Wiethoff, Katja; Baethge, Christopher; Pfennig, Andrea; Stamm, Thomas; Bauer, Michael

doi:10.1080/13651500801911144

Cited by 2 publications

(1 citation statement)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MES consists of 11 items and has demonstrated high psychometric validity in relation to the measurement of severity of major depression . In PD, the MES has been used as primary and secondary outcome measure in studies of psychopharmacological treatments. However, the clinical validity of the MES has not been established for PD.…”

Section: Resultsmentioning

confidence: 99%

Rating scales measuring the severity of psychotic depression

Østergaard

Rothschild

Flint

et al. 2015

Acta Psychiatr Scand

View full text Add to dashboard Cite

Objective Unipolar psychotic depression (PD) is a severe and debilitating syndrome, which requires intensive monitoring. The objective of this study was to provide an overview of the rating scales used to assess illness severity in PD. Method Selective review of publications reporting results on non-self-rated, symptom-based rating scales utilized to measure symptom severity in PD. The clinical and psychometric validity of the identified rating scales was reviewed. Results A total of 14 rating scales meeting the predefined criteria were included in the review. These scales grouped into the following categories: I. Rating scales predominantly covering depressive symptoms, II. Rating scales predominantly covering psychotic symptoms, III. Rating scales covering delusions, and IV. Rating scales covering psychotic depression. For the vast majority of the scales, the clinical and psychometric validity had not been tested empirically. The only exception from this general tendency was the 11-item Psychotic Depression Assessment Scale (PDAS), which was developed specifically to assess the severity of PD. Conclusion In PD, the Psychotic Depression Assessment Scale (PDAS) represents the only empirically derived rating scale for the measurement of overall severity of illness. The PDAS should be considered in future studies of PD and in clinical practice.

show abstract

Section: Resultsmentioning

confidence: 99%

Rating scales measuring the severity of psychotic depression

Østergaard

Rothschild

Flint

et al. 2015

Acta Psychiatr Scand

View full text Add to dashboard Cite

show abstract

Citalopram versus other anti-depressive agents for depression

Cipriani

Purgato

Furukawa

et al. 2012

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode. Systematic reviews have already highlighted some differences in efficacy between second-generation antidepressants. Citalopram, one of the first selective serotonin reuptake inhibitors (SSRI) introduced in the market, is one of these antidepressant drugs that clinicians use for routine depression care. Objectives To assess the evidence for the efficacy, acceptability and tolerability of citalopram in comparison with tricyclics, heterocyclics, other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression. Search methods We searched The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register and the Cochrane Central Register of Controlled Trials up to February 2012. No language restriction was applied. We contacted pharmaceutical companies and experts in this field for supplemental data. Selection criteria Randomised controlled trials allocating patients with major depression to citalopram versus any other antidepressants. Data collection and analysis Two reviewers independently extracted data. Information extracted included study characteristics, participant characteristics, intervention details and outcome measures in terms of efficacy (the number of patients who responded or remitted), patient acceptability (the number of patients who failed to complete the study) and tolerability (side-effects). Main results Thirty-seven trials compared citalopram with other antidepressants (such as tricyclics, heterocyclics, SSRIs and other antidepressants, either conventional ones, such as mirtazapine, venlafaxine and reboxetine, or non-conventional, like hypericum). Citalopram was shown to be significantly less effective than escitalopram in achieving acute response (odds ratio (OR) 1.47, 95% confidence interval (CI) 1.08 to 2.02), but more effective than paroxetine (OR 0.65, 95% CI 0.44 to 0.96) and reboxetine (OR 0.63, 95% CI 0.43 to 0.91). Significantly fewer patients allocated to citalopram withdrew from trials due to adverse events compared with patients allocated to tricyclics (OR 0.54, 95% CI 0.38 to 0.78) and fewer patients allocated to citalopram reported at least one side effect than reboxetine or venlafaxine (OR 0.64, 95% CI 0.42 to 0.97 and OR 0.46, 95% CI 0.24 to 0.88, respectively). Authors’ conclusions Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy, tolerability and acceptability. Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics, reboxetine and venlafaxine, however, it seemed to be less efficacious than escitalopram. As with most systematic reviews in psychopharmacology, the potential for overestimation of treatment effect due ...

show abstract

Olanzapine in the treatment of depression with psychotic features: A prospective open-label study

Cited by 2 publications

References 58 publications

Rating scales measuring the severity of psychotic depression

Rating scales measuring the severity of psychotic depression

Citalopram versus other anti-depressive agents for depression

Contact Info

Product

Resources

About